Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.18 USD | +0.32% | +1.60% | -17.19% |
04-04 | Acumen Pharmaceuticals Signs Deal With Lonza to Manufacture Alzheimer's Treatment Drug | MT |
04-04 | Lonza Enters Manufacturing Agreement for Acumen’s Alzheimer’s Disease Drug Candidate | MT |
Business Summary
Number of employees: 52
Managers
Managers | Title | Age | Since |
---|---|---|---|
Daniel O'Connell
CEO | Chief Executive Officer | 54 | 06-03-31 |
Jim Doherty
PSD | President | 56 | 01-31 |
Matthew Zuga
DFI | Director of Finance/CFO | 58 | 21-04-30 |
Kasey Spencer
CTO | Chief Tech/Sci/R&D Officer | - | - |
Russell Barton
COO | Chief Operating Officer | 66 | 19-03-31 |
Eric Siemers
CTO | Chief Tech/Sci/R&D Officer | 68 | 18-05-31 |
Alexandria Braun
IRC | Investor Relations Contact | - | 22-08-31 |
Kathleen Pierce
PRN | Corporate Officer/Principal | - | - |
Amber Dilley
PRN | Corporate Officer/Principal | - | 20-12-31 |
Jasna Jerecic
PRN | Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Daniel O'Connell
CEO | Chief Executive Officer | 54 | 06-03-31 |
Director/Board Member | 55 | 22-03-31 | |
Jeffrey Ives
BRD | Director/Board Member | 73 | 14-04-30 |
Sean Stalfort
BRD | Director/Board Member | 54 | 18-09-30 |
Derrell Porter
BRD | Director/Board Member | 53 | 23-01-03 |
Laura Stoppel
BRD | Director/Board Member | 38 | 20-10-31 |
Nathan Fountain
BRD | Director/Board Member | 61 | 21-05-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 60,079,778 | 54,596,907 ( 90.87 %) | 0 | 90.87 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.19% | 190M | |
+1.77% | 42.75B | |
+47.70% | 41.61B | |
+12.24% | 41.34B | |
-8.83% | 26.59B | |
+7.44% | 25.49B | |
-23.01% | 18.12B | |
+30.56% | 12.24B | |
-1.82% | 11.76B | |
+8.35% | 11B |
- Stock Market
- Equities
- ABOS Stock
- Company Acumen Pharmaceuticals, Inc.